11 results about "Retinoid" patented technology

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

Provided is a method of producing a fermentation product, the method comprising a first step of preparing a deionized process liquid by removing ions from a process liquid comprising the fermentation product through capacitive deionization (CDI); and a second step of spray-drying the deionized process liquid to obtain the fermentation product without re-crystallization of the fermentation product.

The application discloses a method for simultaneously detecting retinoids and lipid-soluble vitamin metabolic marker groups in biological samples and matching reagents. The application is based on magnetic bead solid-phase extraction technology, significantly improves sample purification effect, and reduces matrix interference; in combination with a high-aqueous-phase reversed-phase chromatography system and a positive-negative ion switching multi-reaction monitoring mode, simultaneous separation and detection of seven retinoid molecules and a full spectrum of lipid-soluble vitamins are realized. The method has high sensitivity, strong specificity and wide detection range, and for the first time realizes one-stop analysis across species and sample types, thereby providing reliable platform support for clinical and scientific research applications.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“Bispecific RBP4 / TTR ligand”) is a chemical entity that binds to both TTR and RBP4 in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

This application relates to a microbial oil composition containing retinoids and fatty acids, a cosmetic composition, a food composition, a feed composition containing the same, and a method for producing the same.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and one or more retinoid compounds, for example, topical compositions of urolithins with one or more retinoids. The invention also relates to uses of such compositions, for use for the treatment or prevention of diseases, disorders and conditions, particularly diseases, disorder or conditions of the skin and hair, and for use in non-therapeutic treatments. The invention also related to a urolithin, for example, urolithin A, for use in reducing adverse effects of the administration of a retinoid compound.

Disclosed is a cosmetic composition comprising: (a) substituted resorcinol-substituted cyclodextrin complex; and (b) emulsion comprising retinoid and glyceride.

The invention relates to an improved process for isomerizing polyunsaturated non-aromatic compounds including acyclic conjugated polyenes and alicyclic conjugated polyenes. In particular it relates to an improved and safe process for forming a 11-E retinoid compounds in high yield by expending as few energy as possible and with avoiding at most possible side products or product mixtures. This is achieved by feeding at least one of retinoid compounds of formula 2 to 5, or at least one of retinoid compounds of formula 2 to 5 and retinoid compound of formula 1, an organic solvent and a photosensitizer into a reaction device and irradiating the thus obtained reaction mixture with visible monochromatic light, at least 90% of the power of said monochromatic light and at most 100% of said power being emitted in the range from 460 nm to 580 nm.

The present invention relates to benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORy) and their pharmaceutical uses, in particular to benzimidazole derivatives of formula (I) as inhibitors of the retinoid-related orphan receptor gamma (RORy) protein, pharmaceutical compositions comprising the compounds, processes for their preparation, and the use of the compounds as therapeutic agents for the treatment of RORy-mediated diseases or conditions.